These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9240185)

  • 41. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
    Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
    Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparison of different drugs on the treatment of benign prostate hyperplasia].
    Li NC; Wu SL; Jin J; Qiu SP; Kong CZ; Song YS; Ye ZQ; Sun G; Sun YH; Sun YC; Wang XF; Na YQ
    Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(14):947-50. PubMed ID: 17961376
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.
    Beduschi MC; Beduschi R; Oesterling JE
    Urology; 1998 Jun; 51(6):861-72. PubMed ID: 9609620
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Garimella PS; Fink HA; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Therapeutic effect of harnal and proscar in treating benign prostatic hyperplasia].
    Tang ZY; Peng KL; Ding J; Zu XB; Qi L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 30(6):708-10. PubMed ID: 16708816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How frequent are invasive therapies required in patients receiving tamsulosin for benign prostatic hyperplasia? A retrospective long-term study.
    Kawabe K; Homma Y; Kubota K; Sozu T;
    Int J Urol; 2006 Feb; 13(2):127-31. PubMed ID: 16563136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinical results and problems of anti-androgen therapy of benign prostatic hypertrophy].
    Umeda K
    Hinyokika Kiyo; 1991 Nov; 37(11):1429-33. PubMed ID: 1722628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized controlled trial.
    Pande S; Hazra A; Kundu AK
    Indian J Pharmacol; 2014; 46(6):601-7. PubMed ID: 25538330
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia.
    Ichioka K; Ohara H; Terada N; Matsui Y; Yoshimura K; Terai A; Arai Y
    Int J Urol; 2004 Oct; 11(10):870-5. PubMed ID: 15479292
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis.
    Debruyne F; Boyle P; Calais Da Silva F; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP; Schulman CC
    Eur Urol; 2004 Jun; 45(6):773-9; disucssion 779-80. PubMed ID: 15149751
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men.
    Corica FA; Jacobsen SJ; King BF; Bostwick DG; Jacobson DJ; Girman CJ; Lieber MM
    J Urol; 1999 Mar; 161(3):831-4. PubMed ID: 10022695
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
    Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
    BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia.
    Cao Y; Wang Y; Guo L; Yang X; Chen T; Niu H
    Med Sci Monit; 2016 Jun; 22():1895-902. PubMed ID: 27260129
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses.
    Lee E; Lee C
    Br J Urol; 1997 Oct; 80(4):606-11. PubMed ID: 9352700
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    McVary KT; Rademaker A; Lloyd GL; Gann P
    J Urol; 2005 Oct; 174(4 Pt 1):1327-433. PubMed ID: 16145413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The short-term effects of tamsulosin in Japanese men with benign prostatic hyperplasia.
    Horiuchi K; Tsuboi N; Hattori T; Yoshida K; Akimoto M
    Nihon Ika Daigaku Zasshi; 1999 Dec; 66(6):382-7. PubMed ID: 10638187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.